US Stock MarketDetailed Quotes
HLVX HilleVax
- 1.860
- +0.040+2.20%
Close Nov 22 16:00 ET
- 1.860
- 0.0000.00%
Post 16:02 ET
92.64MMarket Cap-601P/E (TTM)
1.900High1.830Low126.83KVolume1.830Open1.820Pre Close235.54KTurnover0.42%Turnover RatioLossP/E (Static)49.81MShares20.22052wk High0.50P/B55.65MFloat Cap1.55052wk Low--Dividend TTM29.92MShs Float24.420Historical High--Div YieldTTM3.85%Amplitude1.550Historical Low1.857Avg Price1Lot Size
HilleVax Stock Forum
Sign in to post a comment
$HilleVax (HLVX.US)$ fly to the moon 🌙
2
1
$HilleVax (HLVX.US)$ recovery sure would happen, how much would it pull up??
HilleVax, Inc. Announced Disappointing Results from NEST-IN1 Clinical Study.
On a day that saw its stock plummet by 84%, closing at $2.25, HilleVax, Inc. (Nasdaq: HLVX) announced the topline data results from its NEST-IN1 clinical study. This notable decline followed the announcement that the NEST-IN1 study did not meet its primary or secondary efficacy endpoints, leading the company to discontinue further dev...
On a day that saw its stock plummet by 84%, closing at $2.25, HilleVax, Inc. (Nasdaq: HLVX) announced the topline data results from its NEST-IN1 clinical study. This notable decline followed the announcement that the NEST-IN1 study did not meet its primary or secondary efficacy endpoints, leading the company to discontinue further dev...
$HilleVax (HLVX.US)$
HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants
HilleVax announced topline results from the NEST-IN1 Phase 2b study of HIL-214 in infants. The trial, conducted in the US and Latin America, did not meet its primary or secondary efficacy endpoints. Specifically, the vaccine showed a mere 5% efficacy against moderate or severe acute gastroenteritis caused by norovirus, which was statistically insignificant. Consequently, HilleVax wil...
HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants
HilleVax announced topline results from the NEST-IN1 Phase 2b study of HIL-214 in infants. The trial, conducted in the US and Latin America, did not meet its primary or secondary efficacy endpoints. Specifically, the vaccine showed a mere 5% efficacy against moderate or severe acute gastroenteritis caused by norovirus, which was statistically insignificant. Consequently, HilleVax wil...
how the F they gonna cut the target from 28 down to 2 just because of failed trial? This company has pretty sound finances and their debt to assets is extremely good for this particular field
2
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$HilleVax (HLVX.US)$ friday usd 1.10
1
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Ziggz420 : $ARCA biopharma (ABIO.US)$ still in it
silverelf Ziggz420 : Same![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")